Unia Europejska - francuski - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agents antinéoplasiques - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Unia Europejska - francuski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agents antinéoplasiques - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Belgia - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de bendamustine monohydraté 26,14 mg/ml - eq. chlorhydrate de bendamustine 25 mg/ml - solution à diluer pour perfusion - 25 mg/ml - chlorhydrate de bendamustine monohydraté 26.14 mg/ml - bendamustine

Unia Europejska - francuski - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - le myélome multiple - agents antinéoplasiques - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Unia Europejska - francuski - EMA (European Medicines Agency)

accord healthcare s.l.u. - plérixafor - multiple myeloma; hematopoietic stem cell transplantation - les immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Szwajcaria - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - lenograstimum adnr - granocyte 33,6 poudre et solvant pour solution injectable - praeparatio cryodesiccata: lenograstimum adnr 263 µg corresp. 33.6 mio u.i., mannitolum, polysorbatum 20, natrii chloridum, argininum, phenylalaninum, methioninum, pro vitro. solvens: aqua ad iniectabile 1 ml. - neutropénie - biotechnologika